CTI Biopharma Corp said on Monday its treatment for a type of blood cancer did not meet the main goal of a late-stage trial.
The drug, Pixuvri, was being tested in patients with aggressive B-cell Non-Hodgkin lymphoma. (Reporting by Manas Mishra in Bengaluru)